These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

545 related items for PubMed ID: 26076136

  • 1. Prevention of adult pneumococcal pneumonia with the 13-valent pneumococcal conjugate vaccine: CAPiTA, the community-acquired pneumonia immunization trial in adults.
    Isturiz R, Webber C.
    Hum Vaccin Immunother; 2015; 11(7):1825-7. PubMed ID: 26076136
    [Abstract] [Full Text] [Related]

  • 2. Exploratory efficacy endpoints in the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA).
    Webber C, Patton M, Patterson S, Schmoele-Thoma B, Huijts SM, Bonten MJ, CAPiTA Study Group.
    Vaccine; 2017 Mar 01; 35(9):1266-1272. PubMed ID: 28173960
    [Abstract] [Full Text] [Related]

  • 3. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults.
    Bonten MJ, Huijts SM, Bolkenbaas M, Webber C, Patterson S, Gault S, van Werkhoven CH, van Deursen AM, Sanders EA, Verheij TJ, Patton M, McDonough A, Moradoghli-Haftvani A, Smith H, Mellelieu T, Pride MW, Crowther G, Schmoele-Thoma B, Scott DA, Jansen KU, Lobatto R, Oosterman B, Visser N, Caspers E, Smorenburg A, Emini EA, Gruber WC, Grobbee DE.
    N Engl J Med; 2015 Mar 19; 372(12):1114-25. PubMed ID: 25785969
    [Abstract] [Full Text] [Related]

  • 4. The Community-Acquired Pneumonia immunization Trial in Adults (CAPiTA): what is the future of pneumococcal conjugate vaccination in elderly?
    van Werkhoven CH, Bonten MJ.
    Future Microbiol; 2015 Mar 19; 10(9):1405-13. PubMed ID: 26347153
    [Abstract] [Full Text] [Related]

  • 5. Post hoc analysis of the efficacy of the 13-valent pneumococcal conjugate vaccine against vaccine-type community-acquired pneumonia in at-risk older adults.
    Suaya JA, Jiang Q, Scott DA, Gruber WC, Webber C, Schmoele-Thoma B, Hall-Murray CK, Jodar L, Isturiz RE.
    Vaccine; 2018 Mar 07; 36(11):1477-1483. PubMed ID: 29429807
    [Abstract] [Full Text] [Related]

  • 6. A post-hoc analysis of serotype-specific vaccine efficacy of 13-valent pneumococcal conjugate vaccine against clinical community acquired pneumonia from a randomized clinical trial in the Netherlands.
    Gessner BD, Jiang Q, Van Werkhoven CH, Sings HL, Webber C, Scott D, Gruber WC, Grobbee DE, Bonten MJM, Jodar L.
    Vaccine; 2019 Jul 09; 37(30):4147-4154. PubMed ID: 31155413
    [Abstract] [Full Text] [Related]

  • 7. 13-Valent Pneumococcal Conjugate Vaccine: A Review of Its Use in Adults.
    Plosker GL.
    Drugs; 2015 Sep 09; 75(13):1535-46. PubMed ID: 26242768
    [Abstract] [Full Text] [Related]

  • 8. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.
    Jackson LA, Gurtman A, Rice K, Pauksens K, Greenberg RN, Jones TR, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B.
    Vaccine; 2013 Aug 02; 31(35):3585-93. PubMed ID: 23688527
    [Abstract] [Full Text] [Related]

  • 9. The impact of 13-valent pneumococcal conjugate vaccination on virus-associated community-acquired pneumonia in elderly: Exploratory analysis of the CAPiTA trial.
    Huijts SM, Coenjaerts FEJ, Bolkenbaas M, van Werkhoven CH, Grobbee DE, Bonten MJM, CAPiTA study team.
    Clin Microbiol Infect; 2018 Jul 02; 24(7):764-770. PubMed ID: 29050992
    [Abstract] [Full Text] [Related]

  • 10. Effects of 13-valent pneumococcal conjugate vaccination of adults on lower respiratory tract infections and antibiotic use in primary care: secondary analysis of a double-blind randomized placebo-controlled study.
    van Werkhoven CH, Bolkenbaas M, Huijts SM, Verheij TJM, Bonten MJM.
    Clin Microbiol Infect; 2021 Jul 02; 27(7):995-999. PubMed ID: 32971253
    [Abstract] [Full Text] [Related]

  • 11. Pneumococcal conjugate vaccine use in adults.
    Isturiz RE, Schmoele-Thoma B, Scott DA, Jodar L, Webber C, Sings HL, Paradiso P.
    Expert Rev Vaccines; 2016 Jul 02; 15(3):279-93. PubMed ID: 26651847
    [Abstract] [Full Text] [Related]

  • 12. Post-hoc analysis of a randomized controlled trial: Diabetes mellitus modifies the efficacy of the 13-valent pneumococcal conjugate vaccine in elderly.
    Huijts SM, van Werkhoven CH, Bolkenbaas M, Grobbee DE, Bonten MJM.
    Vaccine; 2017 Aug 03; 35(34):4444-4449. PubMed ID: 28410813
    [Abstract] [Full Text] [Related]

  • 13. Early impact of 13-valent pneumococcal conjugate vaccine on community-acquired pneumonia in children.
    Angoulvant F, Levy C, Grimprel E, Varon E, Lorrot M, Biscardi S, Minodier P, Dommergues MA, Hees L, Gillet Y, Craiu I, Zenkhri F, Dubos F, Guen CG, Launay E, Martinot A, Cohen R.
    Clin Infect Dis; 2014 Apr 03; 58(7):918-24. PubMed ID: 24532543
    [Abstract] [Full Text] [Related]

  • 14. Pneumococcal conjugate vaccine use in adults - Addressing an unmet medical need for non-bacteremic pneumococcal pneumonia.
    Sings HL.
    Vaccine; 2017 Sep 25; 35(40):5406-5417. PubMed ID: 28602602
    [Abstract] [Full Text] [Related]

  • 15. The Impact of the 13-Valent Pneumococcal Conjugate Vaccine on Pneumococcal Carriage in the Community Acquired Pneumonia Immunization Trial in Adults (CAPiTA) Study.
    van Deursen AMM, van Houten MA, Webber C, Patton M, Scott D, Patterson S, Jiang Q, Gruber WC, Schmoele-Thoma B, Grobbee DE, Bonten MJM, Sanders EAM.
    Clin Infect Dis; 2018 Jun 18; 67(1):42-49. PubMed ID: 29324986
    [Abstract] [Full Text] [Related]

  • 16. Theory and strategy for Pneumococcal vaccines in the elderly.
    Namkoong H, Ishii M, Funatsu Y, Kimizuka Y, Yagi K, Asami T, Asakura T, Suzuki S, Kamo T, Fujiwara H, Tasaka S, Betsuyaku T, Hasegawa N.
    Hum Vaccin Immunother; 2016 Jun 18; 12(2):336-43. PubMed ID: 26406267
    [Abstract] [Full Text] [Related]

  • 17. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults.
    Jackson LA, Gurtman A, van Cleeff M, Jansen KU, Jayawardene D, Devlin C, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B.
    Vaccine; 2013 Aug 02; 31(35):3577-84. PubMed ID: 23688526
    [Abstract] [Full Text] [Related]

  • 18. Pneumococcal serotypes in adults hospitalized with community-acquired pneumonia in Greece using urinary antigen detection tests: the EGNATIA study, November 2017 - April 2019.
    Liapikou A, Konstantinidis A, Kossyvaki V, Skiadas J, Menegas D, Méndez C, Beavon R, Begier E, Gessner BD, Milionis H, Tsimihodimos V, Baxevanos G, Argiriadou T, Terrovitou C, Toumbis M, EGNATIA Study Group.
    Hum Vaccin Immunother; 2022 Nov 30; 18(5):2079923. PubMed ID: 35703733
    [Abstract] [Full Text] [Related]

  • 19. Prevention of Community-Acquired Pneumonia with Available Pneumococcal Vaccines.
    Principi N, Esposito S.
    Int J Mol Sci; 2016 Dec 25; 18(1):. PubMed ID: 28029140
    [Abstract] [Full Text] [Related]

  • 20. Pneumococcal pneumonia prevention among adults: is the herd effect of pneumococcal conjugate vaccination in children as good a way as the active immunization of the elderly?
    Prato R, Fortunato F, Martinelli D.
    Curr Med Res Opin; 2016 Dec 25; 32(3):543-5. PubMed ID: 26652736
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.